Sommer Causey, MD
Anesthesiology · Galveston, TXNPI 1003303892
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Abbott at 52.9% of the total. Reporting peaked in 2023 at $2,901 and has fallen 84.1% since, to $462 in 2025. Among anesthesiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $85.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$1K
- Boston Scientific$277
- Painteq LLC$176
- AbbVie$168
- SPR Therapeutics, Inc$134
- plus $322 from 5 others
What the payments were for
- Travel & lodging$2,75355%
- Food & beverage$2,27645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $2,660 |
| Medtronic | 12 | $1,292 |
| Boston Scientific | 7 | $277 |
| Painteq LLC | 1 | $176 |
| AbbVie | 8 | $168 |
| SPR Therapeutics, Inc | 1 | $134 |
| Vertos Medical, Inc. | 1 | $101 |
| Pacira Pharmaceuticals Incorporated | 1 | $82 |
| Nevro Corp. | 1 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Relievant Medsystems, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$1,997
- INTELLIS ADAPTIVESTIM$1,009
- PAINTEQ$176
- SPRINT PNS System$134
- mild Device Kit$101
How this compares
$5,030 in reported general payments places this provider in the 95th percentile of 3,899 anesthesiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 21 | $2,441 |
| Tizanidine Hcl | 32 | $1,117 |
| Gabapentin | 99 | $1,081 |
| Methocarbamol | 40 | $503 |
| Pregabalin | 48 | $430 |
| Meloxicam | 36 | $185 |
Paid to pharmacies, not to this prescriber.
Other anesthesiology in Galveston
- Richard TeamesFort Worth$746K
- Tong GanHouston$700K
- Valentine GibsonRichardson$671K
- James MuellerDallas$636K
- Randy RobbinsPlano$593K
- Gabriel MenaHouston$494K
- Maxim EckmannSan Antonio$349K
- Iden CowanAustin$305K
- Ryan CaseyAustin$287K
- Girish JoshiDallas$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.